Monopar Therapeutics Inc
NASDAQ:MNPR
Intrinsic Value
Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. [ Read More ]
The intrinsic value of one MNPR stock under the Base Case scenario is 0.4163 USD. Compared to the current market price of 0.6275 USD, Monopar Therapeutics Inc is Overvalued by 34%.
Valuation Backtest
Monopar Therapeutics Inc
Run backtest to discover the historical profit from buying and selling MNPR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Monopar Therapeutics Inc
Current Assets | 7.3m |
Cash & Short-Term Investments | 7.3m |
Other Current Assets | 66.4k |
Non-Current Assets | 12.7k |
PP&E | 12.7k |
Current Liabilities | 1.8m |
Accounts Payable | 1.7m |
Accrued Liabilities | 8.4k |
Other Current Liabilities | -10 |
Earnings Waterfall
Monopar Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-8.8m
USD
|
Operating Income
|
-8.8m
USD
|
Other Expenses
|
429k
USD
|
Net Income
|
-8.4m
USD
|
Free Cash Flow Analysis
Monopar Therapeutics Inc
MNPR Profitability Score
Profitability Due Diligence
Monopar Therapeutics Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Monopar Therapeutics Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
MNPR Solvency Score
Solvency Due Diligence
Monopar Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Monopar Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MNPR Price Targets Summary
Monopar Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for MNPR is 2.04 USD with a low forecast of 2.02 USD and a high forecast of 2.1 USD.
Ownership
MNPR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
MNPR Price
Monopar Therapeutics Inc
Average Annual Return | -44.08% |
Standard Deviation of Annual Returns | 14.23% |
Max Drawdown | -99% |
Market Capitalization | 11m USD |
Shares Outstanding | 17 454 900 |
Percentage of Shares Shorted | 3.32% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Wilmette, Illinois and currently employs 9 full-time employees. The company went IPO on 2019-12-19. The firm is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (SOM) in oropharyngeal cancer patients. Its camsirubicin is a clinical stage topoisomerase II-alpha selective novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart. Its MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. The MNPR-202 is an early stage camsirubicin analog for various cancers.
Contact
IPO
Employees
Officers
The intrinsic value of one MNPR stock under the Base Case scenario is 0.4163 USD.
Compared to the current market price of 0.6275 USD, Monopar Therapeutics Inc is Overvalued by 34%.